专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06881825B1 Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues 有权
标题翻译：鉴定促进蛋白质，DNA和病毒的摄取和细胞质和/或核转运的肽
公开(公告)号：US06881825B1
公开(公告)日：2005-04-19
申请号：US09653182
申请日：2000-08-31
申请人： Paul D. Robbins , Zhibao Mi , Raymond Frizzell , Joseph C. Glorioso , Andrea Gambotto
发明人： Paul D. Robbins , Zhibao Mi , Raymond Frizzell , Joseph C. Glorioso , Andrea Gambotto
IPC分类号： A61K38/00 , A61K39/00 , A61K47/48 , A61K48/00 , C07K7/06 , C07K7/08 , C12N15/10 , C40B40/02 , A61K38/04 , C12P21/08
CPC分类号： C40B40/02 , A61K38/00 , A61K39/00 , A61K47/62 , A61K48/00 , C07K7/06 , C07K7/08 , C07K2319/00 , C07K2319/10 , C12N15/1037 , G01N33/6842 , G01N2500/10
摘要： The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of the peptides, and methods of use for the peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro.
摘要翻译：本发明涉及促进载体进入细胞的细胞质和细胞核以及鉴定肽的方法和肽的使用方法的内肽化肽。选择本发明的内化肽的能力是在体内和体外有效地将货物内部化成多种细胞类型。

2. 发明申请

US20100216168A1 METHODS FOR EVALUATING ANGIOGENIC POTENTIAL IN CULTURE 审中-公开
标题翻译：用于评估文化中的生殖潜力的方法
公开(公告)号：US20100216168A1
公开(公告)日：2010-08-26
申请号：US12530541
申请日：2008-03-24
申请人： Jamie Heinzman , Stacey Brower , Jason Bush , Zhibao Mi
发明人： Jamie Heinzman , Stacey Brower , Jason Bush , Zhibao Mi
IPC分类号： G01N33/574
CPC分类号： G01N33/574 , G01N33/5011 , G01N2800/52
摘要： The present invention provides a method of evaluating the angiogenic potential of a tumor, and for predicting the efficacy of anti-angiogenic therapies on an individualized basis. The method of the invention involves preparing an angiogenic signature for malignant cells in culture by assaying for the presence or level of one or more angiogenesis-related factors selected from VEGF/VPF, IL8/CXCL8, TGF-β1, TGF-β2, TGF-β3, bFGF/FGF-2, EGF, PDGF-AA, PDGF-AA/BB, IP-10, and Flt-3 ligand. The angiogenic signature may be prepared from cultures maintained under normoxic and/or hypoxic environments. The invention may be used in conjunction with chemoresponse testing of anti-tumor agents, to predict or suggest a combination therapy for cancer patients.
摘要翻译：本发明提供一种评价肿瘤血管生成潜力的方法，以及用于个体化预测抗血管生成疗法的功效。本发明的方法包括通过测定选自VEGF / VPF，IL8 / CXCL8，TGF-β1，TGF-β1的一种或多种血管生成相关因子的存在或水平来制备培养中恶性细胞的血管生成特征。 2，TGF-βb，3，bFGF / FGF-2，EGF，PDGF-AA，PDGF-AA / BB，IP-10和Flt-3配体。血管生成特征可以由维持在常氧和/或缺氧环境下的培养物制备。本发明可以与抗肿瘤剂的化学应答测试结合使用，以预测或建议癌症患者的联合疗法。

3. 发明授权

US06331565B1 Dicaffeoylquinic acid for treating hepatitis B and the diseases associated with retrovirus, and the new caffeoylquinic acid derivatives 有权
标题翻译：二甲酰奎尼酸用于治疗乙型肝炎和与逆转录病毒相关的疾病，以及新的咖啡酰奎宁酸衍生物
公开(公告)号：US06331565B1
公开(公告)日：2001-12-18
申请号：US09260740
申请日：1999-03-01
申请人： Junxing Dong , Zhongming Tang , Zhibao Mi , Bingji Wang
发明人： Junxing Dong , Zhongming Tang , Zhibao Mi , Bingji Wang
IPC分类号： A01N3710
CPC分类号： A61K31/216
摘要： This invention relates to the new use of dicaffeoylquinic acid derivatives for treating Hepatitis B and diseases associated with retrovirus (such as HIV), the new caffeoylquinic acid derivatives and the composition containing the same.
摘要翻译：本发明涉及二苯甲酰奎尼酸衍生物治疗乙型肝炎和与逆转录病毒（例如HIV）相关的疾病，新的咖啡酰奎尼酸衍生物和含有它们的组合物的新用途。

4. 发明申请

US20120219982A1 METHODS FOR SELECTING ACTIVE AGENTS FOR CANCER TREATMENT 审中-公开
标题翻译：选择活性剂用于癌症治疗的方法
公开(公告)号：US20120219982A1
公开(公告)日：2012-08-30
申请号：US13461079
申请日：2012-05-01
申请人： Zhibao Mi , Dave Gingrich , Mike Gabrin
发明人： Zhibao Mi , Dave Gingrich , Mike Gabrin
IPC分类号： C12Q1/02
CPC分类号： G01N33/5011 , G01N33/57415
摘要： The present invention provides methods for individualizing chemotherapy, and particularly methods for individualizing neoadjuvant chemotherapy. The present invention provides methods for predicting a cancer patient's response to neoadjuvant chemotherapy, including assessing the probability of a positive response upon treatment with candidate agents prior to surgery. In various aspects, the invention involves culturing a monolayer of malignant cells from an explant of a patient's biopsy specimen, such as a transcutaneous biopsy-sized specimen, and testing the malignant cells for resistance or sensitivity to one or a plurality of candidate agents for neoadjuvant therapy. In other aspects, the invention provides methods for accurately scoring and interpreting such assays, and discloses in vitro chemoresponse results that are predictive of a patient's pathological complete response (pCR) upon receiving the corresponding treatment regimen.
摘要翻译：本发明提供个体化化疗的方法，特别是个体化新辅助化疗的方法。本发明提供了预测癌症患者对新辅助化疗的反应的方法，包括评估在手术前用候选药物治疗时的阳性反应的可能性。在各个方面，本发明涉及从患者活组织检查样本例如经皮活组织检查大小的标本的外植体中培养单层恶性细胞，并测试恶性细胞对一种或多种新辅助药物的候选药物的抗性或敏感性治疗。在其他方面，本发明提供了用于准确评分和解释这些测定的方法，并且公开了在接受相应的治疗方案时预测患者病理学完全反应（pCR）的体外化学反应结果。

5. 发明申请

US20090104647A1 METHODS FOR SELECTING ACTIVE AGENTS FOR CANCER TREATMENT 有权
标题翻译：选择活性剂用于癌症治疗的方法
公开(公告)号：US20090104647A1
公开(公告)日：2009-04-23
申请号：US12252073
申请日：2008-10-15
申请人： Zhibao Mi , Dave Gingrich , Mike Gabrin
发明人： Zhibao Mi , Dave Gingrich , Mike Gabrin
IPC分类号： C12Q1/02
CPC分类号： G01N33/5011 , G01N33/57415
摘要： The present invention provides methods for individualizing chemotherapy, and particularly methods for individualizing neoadjuvant chemotherapy. The present invention provides methods for predicting a cancer patient's response to neoadjuvant chemotherapy, including assessing the probability of a positive response upon treatment with candidate agents prior to surgery. In various aspects, the invention involves culturing a monolayer of malignant cells from an explant of a patient's biopsy specimen, such as a transcutaneous biopsy-sized specimen, and testing the malignant cells for resistance or sensitivity to one or a plurality of candidate agents for neoadjuvant therapy. In other aspects, the invention provides methods for accurately scoring and interpreting such assays, and discloses in vitro chemoresponse results that are predictive of a patient's pathological complete response (pCR) upon receiving the corresponding treatment regimen.
摘要翻译：本发明提供个体化化疗的方法，特别是个体化新辅助化疗的方法。本发明提供了预测癌症患者对新辅助化疗的反应的方法，包括评估在手术前用候选药物治疗时的阳性反应的可能性。在各个方面，本发明涉及从患者活组织检查样本例如经皮活组织检查大小的标本的外植体中培养单层恶性细胞，并测试恶性细胞对一种或多种新辅助药物的候选药物的抗性或敏感性治疗。在其他方面，本发明提供了用于准确评分和解释这些测定的方法，并且公开了在接受相应的治疗方案时预测患者病理学完全反应（pCR）的体外化学反应结果。

6. 发明授权

US08187800B2 Methods for selecting active agents for cancer treatment 有权
标题翻译：选择用于癌症治疗的活性剂的方法
公开(公告)号：US08187800B2
公开(公告)日：2012-05-29
申请号：US12252073
申请日：2008-10-15
申请人： Zhibao Mi , Dave Gingrich , Mike Gabrin
发明人： Zhibao Mi , Dave Gingrich , Mike Gabrin
IPC分类号： C12Q1/00
CPC分类号： G01N33/5011 , G01N33/57415
摘要： The present invention provides methods for individualizing chemotherapy, and particularly methods for individualizing neoadjuvant chemotherapy. The present invention provides methods for predicting a cancer patient's response to neoadjuvant chemotherapy, including assessing the probability of a positive response upon treatment with candidate agents prior to surgery. In various aspects, the invention involves culturing a monolayer of malignant cells from an explant of a patient's biopsy specimen, such as a transcutaneous biopsy-sized specimen, and testing the malignant cells for resistance or sensitivity to one or a plurality of candidate agents for neoadjuvant therapy. In other aspects, the invention provides methods for accurately scoring and interpreting such assays, and discloses in vitro chemoresponse results that are predictive of a patient's pathological complete response (pCR) upon receiving the corresponding treatment regimen.
摘要翻译：本发明提供个体化化疗的方法，特别是个体化新辅助化疗的方法。本发明提供了预测癌症患者对新辅助化疗的反应的方法，包括评估在手术前用候选药物治疗时的阳性反应的可能性。在各个方面，本发明涉及从患者活组织检查样本例如经皮活组织检查大小的标本的外植体中培养单层恶性细胞，并测试恶性细胞对一种或多种新辅助药物的候选药物的抗性或敏感性治疗。在其他方面，本发明提供了用于准确评分和解释这些测定的方法，并且公开了在接受相应的治疗方案时预测患者病理学完全反应（pCR）的体外化学反应结果。

7. 发明申请

US20070253968A1 Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses 审中-公开
标题翻译：鉴定促进蛋白质，DNA和病毒的摄取和细胞质和/或核转运的肽
公开(公告)号：US20070253968A1
公开(公告)日：2007-11-01
申请号：US11588479
申请日：2006-10-27
申请人： Paul Robbins , Zhibao Mi , Raymond Frizzell , Joseph Glorioso , Andrea Gambotto , Jeffrey Mai
发明人： Paul Robbins , Zhibao Mi , Raymond Frizzell , Joseph Glorioso , Andrea Gambotto , Jeffrey Mai
IPC分类号： A61K39/00 , A61K48/00 , C07K14/00 , C12N15/00 , C12N5/06
CPC分类号： G01N33/6842 , A61K38/00 , A61K39/00 , A61K47/62 , A61K48/00 , C07K7/06 , C07K7/08 , C07K2319/00 , C07K2319/01 , C07K2319/10 , C12N15/1037 , C40B40/02 , G01N33/6803 , G01N2500/10
摘要： The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell.
摘要翻译：本发明涉及促进载体进入细胞的细胞质和核的吸收和转运的肽的内在化以及用于鉴定这些肽的方法。选择本发明的内化肽的能力是在体内和体外有效地将货物内部化成多种细胞类型。用于鉴定本发明的内化肽的方法包括将靶细胞与肽显示文库一起孵育，分离具有内化特征的肽并确定所述肽将货物内化到细胞中的能力。

8. 发明授权

US07264948B2 Polypeptides for increasing mutant CFTR channel activity 失效
标题翻译：用于增加突变CFTR通道活性的多肽
公开(公告)号：US07264948B2
公开(公告)日：2007-09-04
申请号：US10650435
申请日：2003-08-28
申请人： Paul D Robbins , Raymond Frizzell , Zhibao Mi , Fei Sun
发明人： Paul D Robbins , Raymond Frizzell , Zhibao Mi , Fei Sun
IPC分类号： C07K14/435 , C07K14/47 , A61K38/00
CPC分类号： C07K14/4712 , A61K38/00 , C07K2319/60
摘要： The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, ΔF508 CFTR. The present invention is based on the discovery that reduced binding of cytoplasmic chaperones to the endogenous ΔF508 CFTR, mediated by the presence of CFTR polypeptides, results in restoration of plasma membrane localization and channel activity. The methods and compositions of the invention can be used to restore channel activity in cystic fibrosis subjects carrying genetic defects in the CFTR gene, such as for example, ΔF508 CFTR.
摘要翻译：本发明提供了增强对突变型囊性纤维化跨膜传导调节蛋白（CFTR）的通道活性的方法和组合物。本发明的组合物包含含有CFTR亚结构域的多肽，其被设计为模拟全长突变CFTR蛋白质的折叠缺陷，导致与细胞质伴侣如Hsc / Hsp70和Hdj2的竞争性结合。本发明的方法包括在表达突变型CFTR的细胞中CFTR多肽的转导或重组表达。 CFTR多肽的存在导致显性效应，由此CFTR多肽与内源表达的突变CFTR竞争结合胞质伴侣如Hsc / Hsp70和Hdj2。突变CFTR蛋白包括但不限于DeltaF508 CFTR。本发明基于以下发现：细胞质伴侣与CFTR多肽的存在介导的内源性DeltaF508 CFTR的结合减少导致质膜定位和通道活性的恢复。本发明的方法和组合物可用于恢复在CFTR基因中携带遗传缺陷的囊性纤维化受试者中的通道活性，例如DeltaF508CFTR。

9. 发明申请

US20050074884A1 Identification of peptides that facilitate uptake and cytoplasmic and /or nuclear transport of proteins, DNA and viruses 审中-公开
标题翻译：鉴定促进蛋白质，DNA和病毒的摄取和细胞质和/或核转运的肽
公开(公告)号：US20050074884A1
公开(公告)日：2005-04-07
申请号：US10926893
申请日：2004-08-26
申请人： Paul Robbins , Zhibao Mi , Raymond Frizzell , Joseph Glorioso , Andrea Gambotto
发明人： Paul Robbins , Zhibao Mi , Raymond Frizzell , Joseph Glorioso , Andrea Gambotto
IPC分类号： A61K38/00 , A61K39/00 , A61K47/48 , C07K7/06 , C07K7/08 , C12N15/10 , C40B40/02 , G01N33/68 , G01N33/53 , C12N15/85 , C12N15/86
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K47/62 , C07K7/08 , C07K2319/00 , C07K2319/10 , C12N15/1037 , C40B40/02 , G01N33/6803 , G01N33/6842 , G01N2500/10
摘要： The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell.
摘要翻译：本发明涉及促进载体进入细胞的细胞质和核的吸收和转运的肽的内在化以及用于鉴定这些肽的方法。选择本发明的内化肽的能力是在体内和体外有效地将货物内部化成多种细胞类型。用于鉴定本发明的内化肽的方法包括将靶细胞与肽显示文库一起孵育，分离具有内化特征的肽并确定所述肽将货物内化到细胞中的能力。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式